Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota-Reference-Cited by-同舟云学术

Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota

Published:2019-01 Issue: Volume:18 Page:153473541984637
ISSN:1534-7354
Container-title:Integrative Cancer Therapies
language:en
Short-container-title:Integr Cancer Ther

Author:

Frankel Arthur E.¹^ORCID,Deshmukh Sachin¹,Reddy Amit¹^ORCID,Lightcap John¹,Hayes Maureen¹,McClellan Steven¹,Singh Seema¹,Rabideau Brooks²^ORCID,Glover T. Grant²,Roberts Bruce³,Koh Andrew Y.⁴

Affiliation:

1. University of South Alabama Mitchell Cancer Institute, Mobile, AL, USA

2. University of South Alabama, Mobile, AL, USA

3. Vedanta Biosciences, Cambridge, MA, USA

4. University of Texas Southwestern Medical Center, Dallas, TX, USA

Abstract

The past decade has seen tremendous advances in both our understanding of cancer immunosuppressive microenvironments and colonic bacteria facilitated by immune checkpoint inhibitor antibodies and next generation sequencing, respectively. Because an important role of the host immune system is to communicate with and regulate the gut microbial community, it should not come as a surprise that the behavior of one is coupled to the other. In this review, we will attempt to dissect some of the studies demonstrating cancer immunotherapy modulation by specific gut microbes and discuss possible molecular mechanisms for this effect.

Funder

Comprehensive Cancer Center, University of Alabama at Birmingham

Arlene and Mayer Mitchell Endowed Chair in Oncologic Sciences

Publisher

SAGE Publications

Subject

Complementary and alternative medicine,Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1534735419846379

Reference59 articles.

1. Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials

2. Posttransplant Malignancy